Sir,

The onset of cutaneous herpes zoster (HZ) is due to a reactivation of the varicella zoster virus and it is characterized by a painful vesicular eruption following one or more dermatomes. Post herpetic neuralgia, the most common complication, could develop persisting during months or even years. The HZ is considered the most frequent viral etiology affecting patients with systemic lupus erythematosus (SLE).

Recently, Borda et al. describe the epidemiological characteristics of HZ in a Brazilian population affected with SLE. Fifty-five episodes of HZ were reported in 51 patients. The onset of most of them was 5 years after the SLE diagnosis, and frequently during inactive or mild activity. The majority of patients show a typical distribution and a good response to treatment. Nevertheless, complications such as secondary bacterial infection and post herpetic neuralgia could be present [1-3].

**INCIDENCE**

The HZ incidence is 1.2 - 4.9/1000 affected individuals annually. In SLE patients, this number is significantly higher reaching 16-22/1000 annually. It is to be noticed that it is associated with abnormal cytotoxicity mediated by T cells and aggravated by treatment with corticoids and immunosuppressant [1,2,4,5]. Infection risk factors in patients with SLE in Table I.

**CLINICS**

The classic HZ topography is in general unilateral affecting one dermatome, although 20% of patients could be extended to 3 contiguous dermatomes. Some authors classify this pattern as a disseminated HZ (Figs. 1a and b). A varicelliform eruption could be present in non selected patients and most frequently in immunocompromised ones. In cutaneous disseminated high risk patients visceral compromise i.e. disseminated intravascular clotting, encephalitis,
hepatitis, pneumonitis and pancreatitis among others could complicate [4,5].

Diagnostic methodology shown in Table 2 [1-6].

TREATMENT

It is strongly recommended to initiate antiviral treatment within 72 hours of rash onset. The drugs above mentioned shall be maintained for 7-10 days and for 2 days after all the lesions are covered by a crust (Tabl. 3) [1-4].

Primary medications for acute zoster-associated pain include: analgesics, neuroactive and anticonvulsant agents. Prompt treatment of acute zoster and its associated pain can prevent the development of post herpetic neuralgia. Hospital admission should be considered in these cases:

| Table 1: Infection risk factors in patients with systemic lupus erythematosus |
|---------------------------------|------------------|
| Disease activity                | Anti Sm DNA high titters |
| LES Nephritis                   | Low Complement levels |
| Hemolytic Anemia                | Thrombocytopenia     |
| Leucopenia                      | Antiphospholipid antibodies |
| Prednisone doses higher than 10 mg/d | Cyclophosphamid |
| Corticoids high pulse doses     | Azathioprine         |
| Micophenolate myfedit           | Neoplasia history or present one actual |

Primary medications for acute zoster-associated pain include: analgesics, neuroactive and anticonvulsant agents. Prompt treatment of acute zoster and its associated pain can prevent the development of post herpetic neuralgia. Hospital admission should be considered in these cases:

Table 2: Diagnostic methodology in herpes zoster

- **Vzanck test**
  - **Serology**
    - IgM antibodies by Elisa Kit/recent infection
    - IgG antibodies /previous contact
    - High antibodies titers could be detected HZ in its early onset
    - Viral antigens by immunofluorescence
  - **PCR detection of viral DNA in vesicles aqueous solutions or in cerebrospinal fluid.**

It is to take into account that the serological response could be altered in immunodeprived patients.

Viral cultures are not a common daily practice.

<table>
<thead>
<tr>
<th>Table 3: Treatment with antiviral drugs</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Aciclovir</td>
</tr>
<tr>
<td>2. Famiclovir</td>
</tr>
<tr>
<td>3. Valaciclovir</td>
</tr>
<tr>
<td>4. Brivudin</td>
</tr>
</tbody>
</table>

In case of patients with renal insufficiency drugs 1-2-3 doses must be adjusted. Drugs 2 and 3 have an easier dosing.

In case of resistance foscarnet 60 mg/Kg/12 hours IV is recommended.

VACCINATION

It was introduced in 2006. It is a live attenuated vaccine recommended for 60 years old patients comporting a reactivation risk. In these individuals a diminished HZ incidence (50%) as well as post herpetic neuralgia has been observed (60%). There is no clear evidence to recommend HZ vaccine in patients with SLE. There are researchers that propose that the same rule could be applied to the general population but only in those that are not medicated with immunosuppressors before after vaccination [6-7].

CONCLUSION

Herpes zoster can be a serious problem in systemic lupus erythematosus. Its complications and its antiviral treatment are known, however, the indication of the vaccine to prevent it is not recommended in all patients.

REFERENCES